Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10851 - 10875 of 11900 in total
A phosphodiesterase inhibitor with antidepressant properties. [PubChem]
Experimental
Matched Description: … A phosphodiesterase inhibitor with antidepressant properties. [PubChem] …
Investigational
BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
Investigational
Matched Description: … BL-1020 is a first in class novel compound for the treatment of schizophrenia. …
HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus.
Investigational
Matched Description: … HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the …
Senicapoc (ICA-17043) is a novel Gardos channel blocker. It is being investigated for the treatment of sickle cell disease.
Investigational
Matched Description: … Senicapoc (ICA-17043) is a novel Gardos channel blocker. …
Fluorine-18 is under investigation in clinical trial NCT00870974 (A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions).
Investigational
Matched Description: … Fluorine-18 is under investigation in clinical trial NCT00870974 (A PET Brain Imaging Study of mGluR5 …
Tribulus terrestris is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Tribulus terrestris is a plant/plant extract used in some OTC (over-the-counter) products. …
Chicory leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Chicory leaf is a plant/plant extract used in some OTC (over-the-counter) products. …
Deutivacaftor is under investigation in clinical trial NCT03227471 (A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis).
Investigational
Matched Description: … Deutivacaftor is under investigation in clinical trial NCT03227471 (A Study of VX-445 in Healthy Subjects …
MK-0736 is under investigation in clinical trial NCT00679055 (A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)).
Investigational
Matched Description: … MK-0736 is under investigation in clinical trial NCT00679055 (A Study of How MK-0736 Affects Arterial …
Sepiapterin is under investigation in clinical trial NCT03519711 (A Study of CNSA-001 in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia).
Investigational
Matched Description: … Sepiapterin is under investigation in clinical trial NCT03519711 (A Study of CNSA-001 in Primary Tetrahydrobiopterin …
Mibavademab is under investigation in clinical trial NCT04159415 (Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy).
Investigational
Matched Description: … Mibavademab is under investigation in clinical trial NCT04159415 (Study of REGN4461, a Leptin Receptor …
BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell) for human use (rHSV2hGM-CSF).
Investigational
Matched Description: … BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell …
Petosemtamab is under investigation in clinical trial NCT03526835 (A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors).
Investigational
Matched Description: … Petosemtamab is under investigation in clinical trial NCT03526835 (A Study of Bispecific Antibody MCLA …
Pegtarviliase is under investigation in clinical trial NCT05154890 (A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency).
Investigational
Matched Description: … Pegtarviliase is under investigation in clinical trial NCT05154890 (A Multiple Ascending Dose Study of …
Mivelsiran is under investigation in clinical trial NCT06393712 (A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy).
Investigational
Matched Description: … Mivelsiran is under investigation in clinical trial NCT06393712 (A Phase 2 Trial of ALN-APP in Patients …
Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes.
Experimental
Matched Description: … A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding …
IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Investigational
Matched Description: … IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. ... [A257261] IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With …
GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.
Investigational
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary...
Investigational
Matched Description: … TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical ... of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a
SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult...
Investigational
Matched Description: … cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. ... SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce …
Boron (B) is a chemical element with an atomic number 5 that belongs in the Period 2 and Group 13 in the periodic table. It is a low-abundant metalloid that is a poor electrical conductor at room temperature. Natural boron exists in 2 stable isotopes however pure boron is hard...
Experimental
Matched Description: … It is a low-abundant metalloid that is a poor electrical conductor at room temperature. ... Boron (B) is a chemical element with an atomic number 5 that belongs in the Period 2 and Group 13 in ... There are few pharmaceutical agents that contain a boron molecule in their structures, such as [DB09041 …
The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing proteins. They are expressed predominantly in gastric tissues with the source for them being predominantly stromal cells, although expression of TFF2 mRNA transcripts also occurs with tissue macrophages. The peptides themselves are most...
Investigational
Matched Description: … The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing …
NasoVAX contains replication-deficient adenovirus vectors in suspension. It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells . Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. The compound...
Investigational
Matched Description: … It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial ... As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in ... compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a
DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications. DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. EP3 is a target that associates with increased risk of various vascular...
Investigational
Matched Description: … EP3 is a target that associates with increased risk of various vascular diseases. ... DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention ... DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor …
Displaying drugs 10851 - 10875 of 11900 in total